TY - JOUR
T1 - A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer
AU - Howe, Louise R.
AU - Dannenberg, Andrew J.
N1 - Funding Information:
Supported in part by National Institutes of Health Grant No. CA-89578-01 (AJD) and the Cancer Research Foundation of America (LRH).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Cyclooxygenase-2 (COX-2) is being intensively evaluated as a pharmacologic target for both the prevention and treatment of cancer. Aberrant COX-2 expression was initially described in colorectal cancers and has now been detected in many human tumors, including breast cancers. Strikingly, forced expression of COX-2 in murine mammary gland drives tumor formation. Moreover, knocking out COX-2 protects against the formation of intestinal and skin tumors in animal cancer models. Consistent with these findings, selective COX-2 inhibitors possess anticancer properties. For example, selective COX-2 inhibitors reduce the formation and growth of experimental breast and colon cancers. Importantly, selective COX-2 inhibitors do not inhibit platelet function and cause fewer gastrointestinal side effects (peptic ulcer disease) than traditional nonsteroidal anti-inflammatory drugs. Clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer.
AB - Cyclooxygenase-2 (COX-2) is being intensively evaluated as a pharmacologic target for both the prevention and treatment of cancer. Aberrant COX-2 expression was initially described in colorectal cancers and has now been detected in many human tumors, including breast cancers. Strikingly, forced expression of COX-2 in murine mammary gland drives tumor formation. Moreover, knocking out COX-2 protects against the formation of intestinal and skin tumors in animal cancer models. Consistent with these findings, selective COX-2 inhibitors possess anticancer properties. For example, selective COX-2 inhibitors reduce the formation and growth of experimental breast and colon cancers. Importantly, selective COX-2 inhibitors do not inhibit platelet function and cause fewer gastrointestinal side effects (peptic ulcer disease) than traditional nonsteroidal anti-inflammatory drugs. Clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer.
UR - http://www.scopus.com/inward/record.url?scp=0036312330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036312330&partnerID=8YFLogxK
U2 - 10.1016/s0093-7754(02)70134-6
DO - 10.1016/s0093-7754(02)70134-6
M3 - Article
C2 - 12138405
AN - SCOPUS:0036312330
VL - 29
SP - 111
EP - 119
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 3 SUPPL. 11
ER -